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Abstract
Background: Acute kidney injury (AKI) after out-of-hospital cardiac arrest (OHCA) is a well-known predictor for
mortality. However, the natural course of AKI including recovery rate after OHCA is uncertain. This study investigated
the clinical course of AKI after OHCA and determined whether recovery from AKI impacted the outcomes of OHCA.
Methods: This retrospective multicentre cohort study included adult OHCA patients treated with targeted temperature
management (TTM) between January 2016 and December 2017. AKI was diagnosed using the Kidney Disease:
Improving Global Outcomes criteria. The primary outcome was the recovery rate after AKI and its association with
survival and good neurological outcome at discharge.
Results: A total of 3697 OHCA patients from six hospitals were screened and 275 were finally included. AKI developed
in 175/275 (64%) patients and 69/175 (39%) patients recovered from AKI. In most cases, AKI developed within three
days of return of spontaneous circulation [155/175 (89%), median time to AKI development 1 (1–2) day] and patients
recovered within seven days of return of spontaneous circulation [59/69 (86%), median time to AKI recovery 3 (2–7)
days]. Duration of AKI was significantly longer in the AKI non-recovery group than in the AKI recovery group [5 (2–9) vs.
1 (1–5) days; P < 0.001]. Most patients were diagnosed with AKI stage 1 initially [120/175 (69%)]. However, the number
of stage 3 AKI patients increased from 30/175 (17%) to 77/175 (44%) after the initial diagnosis of AKI. The rate of
survival discharge was significantly higher in the AKI recovery group than in the AKI non-recovery group [45/69 (65%)
vs. 17/106 (16%); P < 0.001]. Recovery from AKI was a potent predictor of survival and good neurological outcome at
discharge in the multivariate analysis (adjusted odds ratio, 8.308; 95% confidence interval, 3.120–22.123; P < 0.001 and
adjusted odds ratio, 36.822; 95% confidence interval, 4.097–330.926; P = 0.001).
Conclusions: In our cohort of adult OHCA patients treated with TTM (n = 275), the recovery rate from AKI after OHCA
was 39%, and recovery from AKI was a potent predictor of survival and good neurological outcome at discharge.
Keywords: Acute kidney injury, Out-of-hospital cardiac arrest, Targeted temperature management, Therapeutic
hypothermia, Survival rate
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Background
Development of acute kidney injury (AKI) after out-of-
hospital cardiac arrest (OHCA) is a well-known predictor
for mortality and poor neurological outcomes in both
adult and paediatric populations [1–6]. However, the nat-
ural course of AKI in terms of its recovery rate after
OHCA is uncertain. Although the incidence and onset of
AKI development have been reported several times, recov-
ery rate after AKI has not been reported to date [3]. If we
know the natural course of AKI after OHCA, it will be
helpful in making appropriate clinical decisions such as
determining the initiation time for renal replacement ther-
apy (RRT) and making a prognosis in OHCA patients with
AKI development. We hypothesised that recovery from
AKI may affect the survival discharge and neurological
status at discharge in OHCA patients treated with tar-
geted temperature management (TTM). Therefore, this
study investigated the clinical course of AKI (from devel-
opment to recovery) after OHCA treated with TTM and
determined whether recovery from AKI has an impact on
the outcomes of OHCA after treatment with TTM.
Methods
Study design and setting
This was a retrospective, multicentre, cohort study. Data
were collected by the review of medical record from the
emergency departments of six academic hospitals located
in South Korea. The study design and plan were approved
by the institutional review boards of each hospital. Writ-
ten informed consent was waived by the institutional re-
view boards. We searched the medical records using the
following diagnostic terminology: ‘death on arrival’, ‘cardiac
arrest with successful resuscitation’, ‘cardiac arrest, un-
specified’, ‘respiratory arrest’ and ‘post-resuscitation state’.
Study population
All adult patients who visited the emergency depart-
ments of the six hospitals for OHCA between January
2016 and December 2017 and were treated with TTM
were screened. The following patients were excluded:
patients aged < 19 years; patients reported dead on ar-
rival to the hospital and did not receive cardiopulmonary
resuscitation (CPR); patients who did not achieve return
of spontaneous circulation (ROSC) despite performing
CPR; patients who did not receive TTM despite achiev-
ing ROSC; patients who were diagnosed with end-stage
renal disease (ESRD) with dialysis (peritoneal dialysis or
haemodialysis) before developing cardiac arrest; patients
who had a do-not-attempt resuscitation (DNAR) order
prior to the development of cardiac arrest; patients who
had acute intracranial haemorrhage or acute ischemic
stroke; and patients who had active bleeding.
Definition of the development of and recovery of AKI
The definition and staging of AKI were based on the diag-
nostic criteria stipulated in the Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines (Additional file 1)
[7]. Development of AKI was diagnosed if one of the cri-
teria was fulfilled (serum creatinine or hourly urine out-
put). If both criteria, the one for serum creatinine and
hourly urine output, were fulfilled to diagnose different
stages of AKI development, higher stage of AKI was diag-
nosed. If the data for the serum creatinine level within the
last 3 months before the development of cardiac arrest
were available, it was regarded as baseline serum creatin-
ine. If this data were unavailable, the lower value between
the estimated serum creatinine level and the first
measured serum creatinine after achieving ROSC was
regarded as baseline serum creatinine [7, 8]. Recovery
from AKI was characterised by the fulfilment of all of the
following conditions (absence of AKI criteria): serum cre-
atinine decreased below the level determined in the
definition of stage 1 AKI and hourly urine output was
maintained over 0.5 mL/kg/h for ≥ 12 h [9].
Variables
Primary outcome variables included the dates of AKI de-
velopment and recovery, the duration of AKI, recovery
rate, and survival discharge. If the AKI stage changed
after the initial diagnosis, the highest stage of AKI was
recorded. Secondary outcome variables included the
following variables recommended by the Utstein resusci-
tation registry templates for OHCA: age (years), sex
(male or female), weight (kg), past medical history
(hypertension, diabetes mellitus, heart failure, or chronic
kidney disease), witnessed arrest (witnessed or not wit-
nessed), arrest location (home, workplace, sports or re-
creation, street or highway, public building, nursing
home, and educational institution), bystander CPR (yes
or no), first monitored rhythm (ventricular fibrillation,
pulseless ventricular tachycardia, pulseless electrical ac-
tivity, and asystole), cause of arrest (medical, trauma,
drug overdose, drowning, electrocution and asphyxia),
response time (time interval from call to visit), defibrilla-
tion time (time interval from call to the time the first
shock), CPR duration (the sum of the prehospital and
emergency room CPR times, min), epinephrine dose
(mg), coronary angiography (yes or no), extracorporeal
membrane oxygenation (yes or no), and targeted
temperature of TTM (33 °C vs. 36 °C). The target
temperature was determined by the physicians in charge
of managing the patients at each institution because
there is no difference in the outcomes between 33 °C
and 36 °C. Therefore, a wide range of target tempera-
tures [from 32 °C to 36 °C] are recommended in institu-
tional standard operating procedures since the
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publication of the 2015 guidelines) [10, 11], maintenance
period of TTM (24 h or 48 h), urine output (mL/kg/h) in
the intensive care unit, event of shock (mean arterial pres-
sure < 70mmHg) after ROSC, daily serum creatinine level
(mg/dL), RRT (yes or no), the type of RRT (continuous
RRT or haemodialysis) and date of RRT (initiation, ter-
mination and duration), discharge date, survival status at
discharge (yes or no) and Modified Rankin Scale (MRS)
score at discharge. If the serum creatinine level was
checked two or more times in a day, the highest value was
recorded. All dates were calculated from the day of ROSC.
The MRS score was used to assess neurological outcomes,
with an MRS score of 0–3 being regarded as a good out-
come and that of 4–6 as a poor outcome [12, 13].
Statistical methods
Descriptive statistics are reported as medians (interquar-
tile range) or means with standard deviation for continu-
ous variables according to the normality of distribution.
The normal distribution of data was analysed using the
Shapiro–Wilk test or Kolmogorov–Smirnov test. Cat-
egorical variables are reported as frequency (percentage).
Demographics and clinical differences between groups
were assessed using Pearson’s chi-squared test or Fisher’s
exact test, as appropriate. Comparisons of variables
between groups were conducted using the two-sided
Student t test or Mann–Whitney U test, as appropriate.
The association between predictors and outcome was
quantified using odds ratio (OR) with 95% confidence
interval (CI). To determine the independent factors asso-
ciated with AKI development, recovery, and outcomes, we
performed multivariate logistic regression analysis initially
including all variables with P value < 0.2; we then applied
a stepwise backward selection of the variables which
remained significant. The Hosmer–Lemeshow test was
used to evaluate the goodness of fit of the logistic regres-
sion model. The Cox regression analysis with time-varying
covariate was used in the survival analysis to calculate the
hazard ratio of AKI with respect to mortality. A P value <
0.05 was considered statistically significant. Statistical ana-
lyses were performed using IBM SPSS version 25.0 (IBM
Corp., Armonk, NY, USA).
Results
Study population
Of the 3697 OHCA patients screened during the study
period, 275 patients treated with TTM at six academic
hospitals in South Korea were enrolled after excluding
3422 patients (Fig. 1). The baseline characteristics of the
study population according to the development of and
recovery from AKI are summarised in Tables 1 and 2.
Fig. 1 Flow chart of the study population. AKI, acute kidney injury; DNAR, do-not-attempt-resuscitation; DOA, death on arrival; ESRD, end-stage
renal disease; ROSC, return of spontaneous circulation; TTM, targeted temperature management
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Descriptive data
The median age of patients was 66 (55–73) years, and
weight was 65 ± 12 kg, with most patients being male
(187/275, 68%). The median time interval from call to ar-
rival of emergency medical service was 7 (5–11) min. The
median duration of CPR was 23 (12–32) min, and median
dose of adrenaline (epinephrine) was 2 (1–4) mg.
Clinical course of AKI
AKI developed in 175/275 (64%) patients and 69/175
(39%) patients recovered from AKI. In total, 169/175
(97%) patients were diagnosed with AKI based on serum
creatinine level and 6/175 (3%) were diagnosed based on
the urine output criteria. In most cases, AKI developed
within three days of ROSC [155/175 (89%), median time
Table 1 Baseline characteristics of the study population according to acute kidney injury development
Variable All patients (n = 275) No AKI (n = 100) AKI (n = 175) P value
Demographics
Male sex 187/275 (68) 70/100 (70) 117/175 (67) 0.591
Age ≥ 60 years 139/275 (51) 40/100 (40) 99/175 (57) 0.008
Weight ≥ 60 kg 178/272 (65) 63/98 (64) 115/174 (66) 0.764
Medical history
Heart failure 7/272 (3) 0/100 (0) 7/172 (4) 0.050
Hypertension 114/273 (42) 30/100 (30) 84/173 (49) 0.003
Diabetes mellitus 67/273 (25) 17/100 (17) 50/173 (29) 0.028
Chronic kidney disease 10/272 (4) 0/100 (0) 10/172 (6) 0.015
Resuscitation
Arrest cause 0.841
Medical or uncertain 224/275 (82) 83/100 (83) 141/175 (81)
Trauma 4/275 (2) 0/100 (0) 4/175 (2)
Poisoning 3/275 (1) 1/100 (1) 2/175 (1)
Drowning 1/275 (0) 1/100 (1) 0/175 (0)
Asphyxia 43/275 (16) 15/100 (15) 28/175 (16)
Arrest location 0.550
Home 134/275 (49) 47/100 (47) 87/175 (50)
Workplace 10/275 (4) 3/100 (3) 7/175 (4)
Sport 6/275 (2) 5/100 (5) 1/175 (1)
Street 65/275 (24) 19/100 (19) 46/175 (26)
Public building 56/275 (20) 24/100 (24) 32/175 (18)
Nursing home 4/275 (1) 2/100 (2) 2/175 (1)
Witnessed arrest 207/275 (75) 80/100 (80) 127/175 (73) 0.170
Bystander CPR 161/275 (59) 58/100 (58) 103/175 (59) 0.890
CPR time ≥ 20 min 135/242 (56) 34/86 (40) 101/156 (65) < 0.001
Shockable rhythm 82/264 (31) 45/95 (47) 37/169 (22) < 0.001
Adrenaline dose ≥ 4 mg 61/225 (27) 11/71 (16) 50/154 (33) 0.008
Post-resuscitation
Shock 186/275 (68) 44/100 (44) 142/175 (81) < 0.001
Coronary angiography 64/275 (23) 34/100 (34) 30/175 (17) 0.001
Target temperature = 33 °C 210/275 (76) 82/100 (82) 128/175 (73) 0.096
TTM duration = 24 h 224/275 (82) 84/100 (84) 140/175 (80) 0.412
Outcomes
Survival discharge 142/275 (52) 80/100 (80) 62/175 (35) < 0.001
MRS score 0 to 3 at discharge 72/275 (26) 47/100 (47) 25/175 (14) < 0.001
P < 0.05 are presented in italics
AKI acute kidney injury, CPR cardiopulmonary resuscitation, MRS modified Rankin Scale, RRT renal replacement therapy, TTM targeted temperature management
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Table 2 Baseline characteristics of the study population according to the recovery of acute kidney injury
Variable All patients with AKI (n = 175) AKI non-recovery group (n = 106) AKI recovery group (n = 69) P value
Characteristics of AKI
AKI stage (initial) < 0.001
Stage 1 120/175 (69) 57/106 (54) 63/69 (91)
Stage 2 25/175 (14) 20/106 (19) 5/69 (7)
Stage 3 30/175 (17) 29/106 (27) 1/69 (2)
AKI stage (highest) < 0.001
Stage 1 68/175 (39) 16/106 (15) 52/69 (75)
Stage 2 30/175 (17) 20/106 (19) 10/69 (15)
Stage 3 77/175 (44) 70/106 (66) 7/69 (10)
Duration of AKI ≥ 4 days 88/175 (50) 66/106 (62) 22/69 (32) < 0.001
RRT frequency 45/175 (26) 41/106 (39) 4/69 (6) < 0.001
RRT duration ≥ 4 days 23/45 (51) 22/41 (54) 1/4 (25) 0.346
†RRT requirements at discharge 4/8 (50) 4/6 (67) 0/2 (0) 0.429
Demographics
Male sex 117/175 (67) 70/106 (66) 47/69 (68) 0.775
Age ≥ 60 years 99/175 (57) 68/106 (64) 31/69 (45) 0.012
Weight ≥ 60 kg 115/174 (66) 71/105 (68) 44/69 (64) 0.600
Medical history
Heart failure 7/172 (4) 6/104 (6) 1/68 (2) 0.247
Hypertension 84/173 (49) 56/105 (53) 28/68 (41) 0.118
Diabetes mellitus 50/173 (29) 37/105 (35) 13/68 (19) 0.022
Chronic kidney disease 10/172 (6) 9/104 (9) 1/68 (2) 0.091
Resuscitation
Arrest cause 0.520
Medical or uncertain 141/175 (81) 88/106 (83) 53/69 (77)
Trauma 4/175 (2) 2/106 (2) 2/69 (3)
Poisoning 2/175 (1) 0/106 (0) 2/69 (3)
Drowning 0/175 (0) 0/106 (0) 0/69 (0)
Asphyxia 28/175 (16) 16/106 (15) 12/69 (17)
Arrest location 0.680
Home 87/175 (50) 57/106 (54) 30/69 (44)
Workplace 7/175 (4) 1/106 (1) 6/69 (9)
Sport 1/175 (1) 0/106 (0) 1/69 (1)
Street 46/175 (26) 27/106 (26) 19/69 (28)
Public building 32/175 (18) 19/106 (18) 13/69 (19)
Nursing home 2/175 (1) 2/106 (2) 0/69 (0)
Witnessed arrest 127/175 (73) 76/106 (72) 51/69 (74) 0.748
Bystander CPR 103/175 (59) 61/106 (58) 42/69 (61) 0.662
CPR time ≥ 20 min 101/156 (65) 71/96 (74) 30/60 (50) 0.002
Shockable rhythm 37/169 (22) 19/101 (19) 18/68 (27) 0.238
Adrenaline dose ≥ 4 mg 50/154 (33) 40/96 (42) 10/58 (17) 0.002
Post-resuscitation
Shock 142/175 (81) 96/106 (91) 46/69 (67) < 0.001
Coronary angiography 30/175 (17) 13/106 (12) 17/69 (25) 0.034
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to AKI development, 1 (1–2) day] and patients recov-
ered within seven days of ROSC [59/69 (86%), median
time to AKI recovery, 3 (2–7) days]. The median dur-
ation of AKI was 4 (2–7) days. Duration of AKI was sig-
nificantly longer in the AKI non-recovery group than in
the AKI recovery group [5 (2–9) vs. 1 (1–5) days; P <
0.001]. Most patients were diagnosed with AKI stage 1
initially [120/175 (69%)]. However, the number of stage
3 AKI patients increased from 30/175 (17%) to 77/175
(44%) after the initial diagnosis of AKI (Table 2). In
addition, the proportions of patients at different AKI
stages varied significantly between AKI non-recovery
and recovery groups (Table 2 and Fig. 2; P < 0.001). RRT
was conducted in 45/175 (26%) patients. The median
duration of RRT was 4 (1–8) days. Use of RRT was sig-
nificantly higher in the AKI non-recovery group than in
the AKI recovery group [41/106 (39%) vs. 4/69 (6%); P <
0.001]. RRT requirements at discharge could only be
evaluated in eight patients (4/8 [50%]), because 37
patients receiving RRT did not survive till discharge
(Table 2). Four of these patients required RRT at dis-
charge, two had fully recovered by discharge, and two
were diagnosed with chronic kidney disease.
Factors associated with AKI development and recovery
In all patients, hypertension and shock were potent pre-
dictors for the development of AKI (Table 3). Among
patients with AKI, hypertension, CPR time ≥ 20min,
AKI stage 3 (highest), and shock were negatively associ-
ated with recovery from AKI (Table 3).
Impact of target temperature on the AKI
After adjusting for age, medical history, witnessed arrest,
CPR time, shockable rhythm, epinephrine dose, shock,
and coronary angiography, the target temperature was
not associated with the development of AKI (the target
temperature was eliminated in step 5 of a stepwise back-
ward selection of variables; OR, 0.670; 95% CI, 0.280–
Table 2 Baseline characteristics of the study population according to the recovery of acute kidney injury (Continued)
Variable All patients with AKI (n = 175) AKI non-recovery group (n = 106) AKI recovery group (n = 69) P value
Target temperature = 33 °C 128/175 (73) 76/106 (72) 52/69 (75) 0.593
TTM duration = 24 h 140/175 (80) 83/106 (78) 57/69 (83) 0.486
Outcomes
Survival discharge 62/175 (35) 17/106 (16) 45/69 (65) < 0.001
MRS score 0 to 3 at discharge 25/175 (14) 3/106 (3) 22/69 (32) < 0.001
P < 0.05 are presented in italics
†Thirty-seven patients receiving renal replacement therapy (RRT) died before discharge. Therefore, whether or not RRT was required could only be assessed in
eight patients
AKI acute kidney injury, RRT renal replacement therapy, CPR cardiopulmonary resuscitation, TTM targeted temperature management, MRS modified Rankin Scale
Initial stage of NRG Highest stage of NRG Initial stage of RG Highest stage of RG


























Fig. 2 Changes in the stage of acute kidney injury after out-of-hospital cardiac arrest. AKI, acute kidney injury; NRG, non-recovery group; RG,
recovery group
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1.601; P = 0.367). In addition, the target temperature was
also not associated with recovery from AKI (OR, 1.207;
95% CI, 0.605–2.411; P = 0.593).
Impact of development of and recovery from AKI on
outcomes
Survival discharge and good neurological outcome at
discharge (MRS scores, 0–3) were observed in a signifi-
cantly higher number of non-AKI patients than in AKI
patients [survival discharge 80/100 (80%) vs. 62/175
(35%); P < 0.001; good neurological outcome, 47/100
(47%) vs. 25/175 (14%); P < 0.001, Table 1]. In addition,
the proportion of patients with survival discharge and
good neurological outcome at discharge was significantly
higher in the AKI recovery group than in the AKI non-
recovery group [survival discharge, 45/69 (65%) vs. 17/
106 (16%); P < 0.001; good neurological outcome 22/69
(32%) vs. 3/106 (3%); P < 0.001].
In multivariate analysis, the development of AKI was
negatively associated with survival discharge (adjusted
OR, 0.238; 95% CI, 0.102–0.555; P = 0.001; Table 4). In pa-
tients with AKI, recovery from AKI was a potent predictor
of survival discharge (adjusted OR, 8.308; 95% CI, 3.120–
22.123; P < 0.001; Table 4). Development of AKI was not
associated with good neurological outcome at discharge;
however, recovery from AKI was a potent predictor of
good neurological outcome at discharge (adjusted OR,
36.822; 95% CI 4.097–330.926; P = 0.001; Table 5).
Subgroup analysis in patients with good neurological
outcomes
There were no significant differences in the distribution
of MRS scores according to AKI development, recovery,
and RRT in the cohort with good neurological outcomes
at discharge (see Additional file 1, Tables S1 to S3). Only
two patients (MRS 2 and 3) were treated with RRT
(Additional file 1: Table S3), one of whom (MRS 3) still
required RRT at discharge.
Recovery rate after AKI according to the stages of AKI
Recovery rate after AKI was significantly higher in pa-
tients with stage 1 AKI than in those with stage 2 or 3
AKI [initial stage: stage 1, 63/120 (53%); stage 2, 5/25
(20%); stage 3, 1/30 (3%); P < 0.001 and highest stage:
stage 1, 52/68 (77%); stage 2, 10/30 (33%); stage 3, 7/77
(9%); P < 0.001).
Survival analysis
Cox regression analysis with time-varying covariate of
AKI showed that patients with AKI had a higher risk of
death than those without AKI (hazard ratio, 2.813; 95%
confidence interval, 1.628–4.859; P < 0.001; Table 6).
Discussion
To the best of our knowledge, the present study is the
first to investigate the recovery rate after AKI and the
association between the recovery from AKI and
Table 3 Factors associated with acute kidney injury development
and recovery in multivariate analysis
Odds ratio 95% confidence interval P value
AKI development
Hypertension 3.011 1.434, 6.322 0.004
Shock 5.654 2.750, 11.626 < 0.001
AKI recovery
Hypertension 0.357 0.137, 0.930 0.035
CPR time ≥ 20min 0.275 0.104, 0.730 0.010
AKI stage 3 (highest) 0.130 0.040, 0.420 0.001
Shock 0.173 0.049, 0.605 0.006
P < 0.05 are presented in italics
AKI acute kidney injury, CPR cardiopulmonary resuscitation
AKI development: Hosmer and Lemeshow test: chi-square = 0.537; df = 4; P = 0.970
AKI recovery: Hosmer and Lemeshow test: chi-square = 8.980; df = 7; P = 0.254
Table 4 Factors associated with survival discharge in multivariate analysis
Odds ratio 95% confidence interval P value
All patients
Adrenaline dose ≥ 4 mg 0.428 0.187, 0.978 0.044
Shock 0.089 0.034, 0.232 < 0.001
Coronary angiography 10.955 3.412, 35.172 < 0.001
AKI 0.238 0.102, 0.555 0.001
AKI patients
Shock 0.178 0.051, 0.626 0.007
Coronary angiography 12.084 3.116, 46.856 < 0.001
AKI recovery 8.308 3.120, 22.123 < 0.001
P < 0.05 are presented in italics
AKI acute kidney injury
All patients: Hosmer and Lemeshow test: chi-square = 8.954; df = 7; P = 0.256
AKI patients: Hosmer and Lemeshow test: chi-square = 5.315; df = 4; P = 0.256
Park et al. Critical Care          (2019) 23:256 Page 7 of 11
outcomes after OHCA in patients treated with TTM. Al-
though the natural course of AKI and the relationship
between AKI and clinical outcomes in other critical care
areas such as sepsis have been previously investigated,
the clinical outcomes in post-cardiac arrest care are still
uncertain [14].
The overall incidence of AKI in our cohort (64%) was
slightly higher than the weighted mean prevalence of
AKI (52%; range, 37–81%) in a previous systematic re-
view because the proportion of patients with a non-
shockable rhythm in our cohort was high (69%) [3]. In
South Korea, non-shockable rhythms occupy a large
proportion of initial rhythms [15]. Because shockable
rhythms are associated with a significantly lower risk of
developing AKI, the incidence of AKI in our cohort
might be higher than that in previous reports [4, 6]. The
same reason may have affected the low recovery rate
after AKI in our cohort (39%); however, the proportions
of shockable rhythms were not significantly different be-
tween the AKI non-recovery and recovery groups [19/
101 (19%) vs. 18/68 (27%); P = 0.238]. A previous study
reported that the renal function returned to normal be-
fore hospital discharge in 67/83 (81%) survivors [3]. In
our results, the recovery rate increased up to 73% when
we considered only the patients with survival discharge
(45/62 patients). However, we could not determine
whether the recovery rate after AKI would be different
depending on the proportion of shockable rhythms.
Thus, further studies including higher proportion of
shockable rhythms are needed.
In contrast to the negative association between the de-
velopment of AKI and survival discharge, there was a
strong positive association between recovery from AKI
and outcomes (acceptance of our hypothesis). This asso-
ciation may be caused by changes in the AKI stages after
the initial diagnosis of AKI because an increase in the
proportion of patients with stage 3 AKI led to an in-
crease in mortality in this study. In the case of the AKI
non-recovery group, the proportion of patients with
stage 3 AKI increased from 27 to 66% (Fig. 2).
The association between the development of AKI and
neurological outcome had been reported several times
[1, 4]. Although the development of AKI was signifi-
cantly associated with survival at discharge, it was not
associated with good neurological outcome at discharge.
This might be attributed to small number of partici-
pants. However, multivariate analysis showed that recov-
ery from AKI was a potent predictor of survival and
good neurological outcome at discharge. Naturally, we
should interpret these results carefully because the char-
acteristics of the OHCA patients are significantly differ-
ent from critical care patients, such as those with severe
sepsis [14, 16]. Whole body ischaemia and reperfusion
leads to post-cardiac arrest syndrome, including brain
injury, myocardial dysfunction, systemic ischaemia, and
reperfusion response [16]. Various factors, including the
duration of ischaemia, cause of cardiac arrest, OHCA in-
terventions, and the patient’s baseline health status,
could affect neurological outcomes in OHCA patients.
Therefore, to determine whether the development of
and recovery from AKI could affect the long-term
neurological and functional outcomes of OHCA pa-
tients, further studies are warranted. In addition, pa-
tients’ death before recovery of AKI could exaggerate
the outcome of the AKI recovery group compared to
that of the AKI non-recovery group. In addition, pa-
tients’ death before the recovery of AKI might be caused
Table 5 Factors associated with good neurological outcome in
multivariate analysis
Odds ratio 95% confidence interval P value
All patients
Shockable rhythm 3.085 1.057, 9.006 0.039
CPR time ≥ 20min 0.235 0.081, 0.679 0.007
Shock 0.160 0.055, 0.465 0.001
Coronary angiography 14.087 4.291, 46.248 < 0.001
AKI patients
Coronary angiography 12.644 2.712, 58.952 0.001
AKI recovery 36.822 4.097, 330.926 0.001
P < 0.05 are presented in italics
AKI acute kidney injury, CPR cardiopulmonary resuscitation
All patients: Hosmer and Lemeshow test: chi-square = 5.207; df = 6; P = 0.518
AKI patients: Hosmer and Lemeshow test: chi-square = 0.733; df = 2; P = 0.693
Table 6 Cox regression analysis with time-varying covariate of development of acute kidney injury showing the effect of five
variables on the risk of death
Variable Coefficient Standard Error Wald P value Hazards ratio 95% CI
Witnessed arrest −0.485 0.218 4.968 0.026 0.615 0.402, 0.943
Adrenaline dose ≥ 4 mg 0.611 0.211 8.419 0.004 1.843 1.219, 2.784
Coronary angiography −1.629 0.468 12.138 < 0.001 0.196 0.078, 0.490
Shock 1.446 0.374 14.976 < 0.001 4.244 2.041, 8.826
†T_COV_AKI 1.034 0.279 13.746 < 0.001 2.813 1.628, 4.859
P < 0.05 are presented in italics
†T_COV_AKI means time-varying covariate of AKI development
AKI acute kidney injury, CI confidence interval
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by reasons (competing risk problems) other than AKI
[17]. To decrease competing risk problems, we con-
ducted subgroup analysis after excluding patients who
died within 48 h since ROSC (Additional file 1: Table
S4). Development of and recovery from AKI were sig-
nificant predictors of survival discharge in the multivari-
ate analysis even after excluding patients who died
within 48 h (Additional file 1: Table S5). In addition, re-
covery from AKI was a potent predictor of good neuro-
logical outcome at discharge in patients with AKI
(Additional file 1: Table S6). Most of the results of the
multivariate analysis did not change after excluding pa-
tients who died within 48 h since ROSC.
Neither the incidence of AKI nor recovery of AKI was
significantly influenced by target temperature (33 °C vs.
36 °C) in our cohort. However, the exact effect of target
temperatures on the development of AKI could not be
determined in this study because the target temperature
was not randomised in our cohort. Recently, the post
hoc analysis of TTM trial (randomised clinical trial for
comparing the TTM 33 °C versus 36 °C after OHCA)
[10] for evaluating the effect of target temperature on
the development of AKI has been reported [18, 19]. Al-
though the incidence of AKI was higher in the TTM-33
group compared to that in the TTM-36 group (49% ver-
sus 40%), there was no association between the target
temperature and development of AKI based on the lo-
gistic regression analysis [18]. We could not determine
whether there was a difference in the recovery rate of
AKI according to the target temperature because the re-
covery rate according to the target temperature had not
been reported in that study.
The appropriate time to initiate RRT in a critical care
setting has not been defined [20]. Studies on the issues of
early versus delayed initiation of RRT show heterogeneous
results in a critical care setting [21–23]. In the case of
OHCA treated with TTM, studies on early initiation of
RRT have not yet been conducted. In our cohort, RRT
was mostly conducted after the patient reached Stage 3
AKI (95%). Therefore, we could not verify the preventive
effect of RRT in our study. Another study including a
large cohort is warranted to verify the effect of RRT on
the outcomes of the OHCA treated with TTM.
Limitations
The present study has several limitations. First, there was
a higher risk of selection bias because the data of the
present study were collected retrospectively. A prospective
study will be needed to confirm our findings. Second, al-
though the present study was conducted using a multicen-
tre cohort, the size of the cohort was relatively small. In
addition, all study sites were located in South Korea.
Therefore, our results cannot be representatives of all
OHCA patients. Third, determining the development of
and recovery from AKI based on serum creatinine level
could lead to underestimation of the development of AKI
or overestimation of recovery from AKI compared to an
approach based on the estimated glomerular filtration rate
calculated from cystatin C [24]. In addition, decreased
muscle metabolism in critically ill patients could also lead
to an overestimation of renal function [25]. Therefore, the
incidence and recovery rates of AKI in our cohort might
be affected by the use of serum creatinine levels to diag-
nose AKI in most patients. Fourth, we could not deter-
mine the effect of RRT in the present study because most
of the patients (80%) treated with RRT did not survive to
discharge. Further studies are needed to evaluate the effi-
cacy of RRT in OHCA patients treated with TTM. Fifth,
although we determined the development of AKI by con-
sidering both serum creatinine level and hourly urine out-
put, we did not record the data on hourly urine output.
Therefore, serial changes in hourly urine output could not
be presented in the results. Sixth, only a small number of
patients were included from the screened OHCA patients
(275/3,697 [7%]). In South Korea, the emergency medical
service providers do not have the legal right to declare
death. All patients with OHCA are transported to the
emergency to confirm death, with or without CPR, even if
they show obvious signs of death (e.g. postmortem lividity
and rigour mortis). Therefore, 71% (2619/3697) of the
screened patients were initially excluded from our cohort.
The important exclusion was the absence of treatment
with TTM (443/3697 patients [12%]). There were several
reasons for this exclusion. Most of the institutions in
South Korea use surface cooling or intravascular cooling
devices for strict temperature control, including rewarm-
ing speed. However, the disposable components of these
devices are not covered by the South Korean national
health insurance system. Approximately 1500 to 3500
USD is needed for TTM treatment, in addition to the
basic costs of post-cardiac arrest care and intensive care.
Therefore, some of the patients’ legal surrogates did not
agree to TTM. In addition to the financial issue, TTM it-
self has several contraindications. For example, refractory
shock that does not respond to fluid or vasopressors, se-
vere sepsis, poor neurological condition before cardiac ar-
rest, pregnancy, arrhythmia that does not respond to
treatment or coronary vasospasm, active bleeding or
thrombolytic use, terminal illness before cardiac arrest,
DNAR orders, and comatose patients with other aetiol-
ogies. The above reasons might have limited patient inclu-
sion in the present study.
Conclusions
In our cohort of adult OHCA patients treated with TTM
(n = 275), the recovery rate from AKI after OHCA was
39%, and recovery from AKI was a potent predictor of
survival and good neurological outcome at discharge.
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Additional file
Additional file 1: Table S1. The distribution of modified Rankin Scale
scores according to the development of acute kidney injury in patients
with good neurological outcomes at discharge. Table S2. The distribution
of modified Rankin Scale scores according to the recovery from acute
kidney injury in patients with good neurological outcomes at discharge.
Table S3. The distribution of modified Rankin Scale scores according to
renal replacement therapy in patients with good neurological outcomes at
discharge. Table S4. Baseline characteristics of the study population
according to the recovery of acute kidney injury after excluding patients
who died within 48 h since return of spontaneous circulation. Table S5.
Factors associated with survival discharge in multivariate analysis after
excluding patients who died within 48 h since return of spontaneous
circulation. Table S6. Factors associated with good neurological outcome in
multivariate analysis after excluding patients who died within 48 h since
return of spontaneous circulation. (DOCX 22 kb)
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